News
$Capricor Therapeutics (CAPR.US)$ Reuters· just
Capricor Therapeutics Announces Positive 3-Year Efficacy Results From Hope-2 Open Label Extension Study of Cap-1002 in Duchenne Muscular Dystrophy
Capricor Therapeutics Announces Positive 3-Year Efficacy Results From Hope-2 Open Label Extension Study of Cap-1002 in Duchenne Muscular Dystrophy
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment